Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26.
Cereno Scientific’s recent capital markets day (CMD) centered on CS1’s progression from early clinical validation into Phase IIb development...
We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected t...
Cereno Scientific’s Q225 results demonstrated steady progress across its clinical assets, with encouraging developments post-period.
Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the way for Phase II studies in idiopathic ...
Cereno Scientific has released its Q324 results, marking a productive and strategically significant period.
Cereno Scientific recently held a capital markets day (CMD), providing greater insight on its development pipeline and strategic objectives.
Cereno Scientific has reported positive top-line results for the Phase IIa CS1-003 trial, which evaluated the HDAC inhibitor CS1 in pulmonar...
Cereno Scientific’s lead asset CS1 has been granted the Orphan Medicinal Product Designation (OMPD) from the European Commission as a potent...
Cereno Scientific has announced its Q224 results, reflecting tangible progress with its clinical candidates.
Cereno Scientific has released updates on its two most advanced clinical programmes.
The European Medicines Agency (EMA) has approved Cereno Scientific’s Clinical Trial Application (CTA) for CS014, a novel HDAC inhibitor with...
Cereno Scientific’s Q124 results provided a financial update and recapped the company’s clinical plans and progress.
Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clini...
Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches.
Redeye comments on Cereno Scientific’s Q2 2023 report.
Redeye comments on Cereno Scientific’s Q1 2023 report and the outcome of the rights issue.
Redeye comments on Cereno Scientific’s Q1 report and notes important key activities carried out in the quarter.
Redeye comments on Cereno Scientific’s rights issue that was announced yesterday.
Redeye comments on Cereno Scientific’s in-licensing agreement with CS585.
Redeye comments on Cereno Scientific’s Q4 2022 report.
Redeye comments on Cereno Scientific’s Q3 2022 report.
Redeye comments on the outcome of Cereno Scientific’s warrants of series TO2.
Redeye revisits its view of Cereno Scientific before the imminent TO2 exercise and coming phase II data from the company’s trial with lead c...
Redeye comments on Cereno’s Q2 2022 report, and we judge that the company is making solid progress on all fronts.
Redeye is encouraged by Cereno Scientific announcing first-patient-in for its phase II study with lead candidate CS1 in PAH.
Redeye provides a brief comment on Cereno’s Q1 2022 report.
Redeye comments on Cereno’s Q4 2021 report, concluding a year in which the company has made several investments that will hopefully start be...
Cereno Scientific står redo att genomföra en fas II-studie med läkemedelskandidaten CS1 mot pulmonell arteriell hypertension.
Redeye is encouraged by FDA approving Cereno’s IND application to start its phase II trial in pulmonary arterial hypertension with lead cand...
Redeye briefly comments on Cereno’s Q2 2021 report, which came without any surprises.
Redeye initiates coverage of Cereno Scientific, a biotech company developing drugs to treat both rare and common cardiovascular diseases.
